William Blair Investment Management LLC Purchases New Stake in ADMA Biologics Inc $ADMA

William Blair Investment Management LLC purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA) during the 4th quarter, Holdings Channel.com reports. The fund purchased 890,861 shares of the biotechnology company’s stock, valued at approximately $16,249,000.

Several other hedge funds have also recently bought and sold shares of ADMA. Royal Bank of Canada raised its holdings in ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after buying an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC purchased a new position in ADMA Biologics in the first quarter valued at approximately $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after buying an additional 305,064 shares during the period. Norges Bank purchased a new position in ADMA Biologics in the second quarter valued at approximately $549,000. Finally, EverSource Wealth Advisors LLC raised its holdings in ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,180 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the transaction, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.90% of the company’s stock.

ADMA Biologics Stock Performance

ADMA opened at $8.24 on Tuesday. The firm has a market capitalization of $1.91 billion, a P/E ratio of 12.12 and a beta of 0.83. The firm’s 50 day moving average is $10.34 and its 200-day moving average is $14.89. ADMA Biologics Inc has a 52-week low of $7.21 and a 52-week high of $22.37. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the firm posted $0.11 earnings per share. Analysts expect that ADMA Biologics Inc will post 0.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on ADMA shares. Zacks Research lowered shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Mizuho dropped their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Canaccord Genuity Group dropped their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, ADMA Biologics presently has an average rating of “Hold” and a consensus target price of $19.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.